Supernus and Indivior detail merger of equals in August 3 investor presentation

Supernus Pharmaceuticals and Indivior Pharmaceuticals held a conference call and webcast on August 3, 2026 to discuss their previously announced merger of equals, according to an 8-K filed by Supernus. The companies hosted the call at 8:30 a.m. Eastern Time to present information regarding the proposed merger.¹

Under the deal terms, the transaction is structured as a 100% tax-free stock-for-stock merger in which Supernus shareholders will receive 1.5401 Indivior shares for each Supernus share. Before closing, Indivior will declare a $1 billion aggregate dividend to its pre-closing stockholders. Post-close ownership is set at 56.5% for Indivior shareholders and 43.5% for Supernus shareholders.¹ Governance will include four directors from each company, with Tony Kingsley as non-executive board chair and Jack Khattar continuing as President and CEO. The combined company will be named Supernus, Inc. and headquartered in Rockville, Maryland.¹ The companies are targeting a close in the fourth quarter of 2026, subject to shareholder votes at both companies and regulatory approvals.¹

Financially, the combination creates a portfolio of 11 medicines across four therapeutic areas: addiction, ADHD, postpartum depression, and Parkinson's disease, with expected annual cost synergies of at least $125 million.¹ On a pro forma basis for the twelve months ended June 30, 2026, the combined company reported total net revenue of $2,162 million, Adjusted EBITDA of $888 million, and net leverage under 1x.¹

The filing carries standard risk disclosures. The companies stated that completion of the proposed merger as described is not guaranteed.¹ Investors are directed to a forthcoming joint proxy statement/prospectus for additional detail once filed with the SEC.